Highest-materiality recent filing
Lexicon Q1 net loss narrows to $1M on $21.1M revenue; pipeline on track
Total revenues $21.1M (vs $1.3M), including $20M Novo Nordisk milestone; net loss $1.0M (vs $25.3M).
Lexicon secures $100M loan facility from Hercules Capital; $55M funded at closing
Initial $55M tranche drawn at closing to repay existing Oxford Finance loan; second $20M and third $25M tranches available subject to milestones.
Lexicon doubles authorized shares to 900M, adopts expanded 2026 equity plans
Authorized common stock increased from 450M to 900M via Seventh Amended and Restated Certificate of Incorporation.
Lexicon Q4 net loss narrows to $15.5M; cash strengthened with $106.7M added in Feb 2026
Q4 net loss $15.5M ($0.04/share) vs $33.8M loss ($0.09/share) in Q4 2024; full-year loss $50.3M.
Public offering of 32M shares at $1.30/share raises ~$41.6M gross; underwriters have 30-day option for 4.8M more shares.
Underwritten public offering of common stock launched; Jefferies and Piper Sandler joint book-running managers.
Lexicon corrects prospectus error on EY internal control audit exemption
Prospectus supplement inadvertently stated EY audited internal controls as of Dec 31, 2024.
Lexicon Q3 2025 net loss narrows to $12.8M; pipeline advances with FDA milestones on track
Q3 revenue $14.2M (from $1.8M YoY) driven by $13.2M Novo Nordisk licensing; net loss $12.8M vs $64.8M prior year.
Lexicon files prospectus supplement for $75M ATM equity facility; no sales to date
Filed prospectus supplement for at-the-market offering of up to $75M of common stock through Jefferies LLC.
Lexicon Q2 net income of $3.3M vs loss; licensing revenue from Novo Nordisk drives top line
Total revenues $28.9M (vs $1.6M Q2'24) driven by $27.5M licensing from Novo Nordisk LX9851 deal.
Lexicon regains Nasdaq minimum bid price compliance; deficiency closed
Received letter from Nasdaq on July 23, 2025 confirming compliance with $1 minimum bid price rule.
Lexicon gets Nasdaq 180-day extension to regain $1 bid; stock moves to Capital Market
Nasdaq granted additional 180-day period until Dec 30, 2025 for Lexicon to cure $1 bid price deficiency.
Shareholders approved reverse stock split at ratio 1-for-10 to 1-for-50, at board discretion before 2026 annual meeting.
Lexicon Q1 net loss narrows to $25.3M; Novo Nordisk license for LX9851, pipeline progress
Net loss of $25.3M ($0.07/sh) vs $48.4M ($0.20/sh) in Q1 2024; revenue $1.3M.
Lexicon licenses LX9851 to Novo Nordisk for $45M upfront; amends Oxford loan with $45M prepayment
Exclusive worldwide license to Novo Nordisk for LX9851 (obesity/cardiometabolic); Lexicon receives $45M upfront, eligible for up to $485M regulatory/commercial milestones and $475M sales milestones.
Lexicon reports Q4 net loss $33.8M; pilavapadin 10mg advances to Phase 3
Q4 net loss $33.8M ($0.09/shr) vs $49.8M loss in Q4 2023; revenue $26.6M including $25M Viatris upfront.
Lexicon Pharmaceuticals receives Nasdaq bid-price deficiency notice; 180 days to cure
Nasdaq notified Lexicon on Jan 3, 2025 that bid price closed below $1 for 31 consecutive business days.
Lexicon appoints Scott M. Coiante as CFO; base salary $450K, option for 230K shares
Scott M. Coiante named SVP and CFO effective Jan 2, 2025; Kristen Alexander remains principal accounting officer.
Lexicon cuts workforce 60%, halts commercial ops after FDA setback on ZYNQUISTA
FDA issued 'deficiencies preclude discussion' letter for ZYNQUISTA (sotagliflozin) NDA in type 1 diabetes and CKD.
Lexicon appoints Ivan Cheung to board as Lefkowitz retires after 23 years
Robert J. Lefkowitz, M.D. retires from board effective Dec 2, 2024; no disagreement cited.
Lexicon Q3 net loss $64.8M; ZYNQUISTA PDUFA Dec 20 after negative AdCom vote
Net loss $64.8M ($0.18/share) vs $50.5M ($0.21) year ago; revenue $1.8M from INPEFA sales.
Lexicon licenses sotagliflozin ex-US/Europe to Viatris for $25M upfront plus milestones
Exclusive license to Viatris for sotagliflozin development and commercialization outside US and Europe.
Jeffrey Wade's employment as president, COO and principal financial officer terminates Sep 30, 2024.
Lexicon Q2 net loss $53.4M; INPEFA sales $1.6M; ZYNQUISTA NDA resubmitted
Net loss $53.4M ($0.17/sh) vs $44.9M a year ago; cash & investments $310M, up from $170M.
New CEO Michael Exton, Ph.D., former Novartis cardiometabolism head, to lead Lexicon starting July 8, 2024.
Lexicon amends Oxford loan: interest-only period to May 2027, maturity to March 2029
Amortization date extended to May 1, 2027; maturity date extended to March 1, 2029.
Lexicon converts all preferred to 115M common; authorized shares increased to 450M
2,304,147 shares of Series A Preferred automatically converted into 115,207,350 common shares on May 10, 2024.
Lexicon Q1 net loss $48.4M; INPEFA sales $1.1M, up 63% QoQ
Net loss of $48.4M ($0.20 per share) vs $31.9M ($0.17) in Q1 2023; SG&A jumped to $32.1M on launch spending.
Lexicon CEO Lonnel Coats to retire effective July 7, 2024; board begins CEO search
Lonnel Coats notified retirement as CEO (principal executive officer) and board member, effective July 7, 2024.
Each Preferred share converts into 50 common shares upon stockholder approval to increase authorized shares to 450M.
Lexicon raises $250M via convertible preferred stock; Q4 net loss widens to $48.2M
Gross proceeds of ~$250M from 2.3M Series A Convertible Preferred shares at $108.50 each, convertible into 115.2M common shares upon stockholder approval of charter increase to 450M shares.
Minimum cash balance of $10M ($25M if fourth tranche drawn) now immediately effective.
Lexicon enters $75M at-the-market equity offering agreement with Jefferies
Company may sell up to $75M of common stock through Jefferies in at-the-market offerings.
Effective as of January 2, 2025, Scott M. Coiante was appointed as our senior vice president and chief financial officer, in which capacity he will function as our principal financial officer.
Kristen L. Alexander, our vice president, finance and accounting, relinquished her function as our principal financial officer.
On November 19, 2024, Robert J. Lefkowitz, M.D. notified us of his decision to retire from our board of directors, effective as of December 2, 2024.
On November 19 , 2024, our board of directors elected Ivan H. Cheung to serve as a member of our board of directors, effective as of December 2, 2024.
Effective as of the date of termination of Mr. Wade’s employment, Kristen L. Alexander will assume the function of our principal financial officer.
On September 13, 2024, we and Jeffrey L. Wade determined that his employment as our president and chief operating officer (in which capacity, Mr. Wade has functioned as our principal financial officer) would terminate as of September 30, 2024.
Michael Exton, Ph.D. was appointed as our chief executive officer
elected to serve as a member of our board of directors
On April 24, 2024, Lonnel Coats notified us of his retirement as our chief executive officer (in which capacity, Mr. Coats functions as our principal executive officer) and as a member of our board of directors, in each case effective July 7, 2024.
On April 24, 2024, Lonnel Coats notified us of his retirement as our chief executive officer (in which capacity, Mr. Coats functions as our principal executive officer) and as a member of our board of directors, in each case effective July 7, 2024.
Max materiality 0.90 · Median 0.70 · Most common event other_material